Skip to main content

Detail

Dagmar Kollmann
Dr. med. univ. Dagmar Kollmann, PhD

Department of Surgery (Division of General Surgery, Division of Transplantation)
Position: Doctor-in-training

ORCID: 0000-0002-7417-237X
dagmar.kollmann@meduniwien.ac.at

Keywords

Clinical Immunology; Kidney Transplantation; Liver Transplantation; oesophageal cancer; Organ Preservation; Reperfusion Injury; Upper Gastrointestinal Tract

Research interests

Ex vivo liver perfusion - Basic research and clinical application of hypothermic and normothermic ex vivo liver perfusion

Liver/Kidney Transplantation - Clinical Research, Translational Research, Biomarker

Upper GI Tract - Esophageal Cancer, Tumor Immunology

Techniques, methods & infrastructure

  • Clinical ex vivo liver perfusion
  • Large animal liver transplantation and experimental ex vivo organ perfusion
  • Standard laboratory techniques (ELISA, Immunhistochemistry, Western Blot, etc.)
  • Clinical Research (Large data analysis)

Selected publications

  1. Kollmann, D. et al., 2018. Living Donor Liver Transplantation Using Selected Grafts With 2 Bile Ducts Compared With 1 Bile Duct Does Not Impact Patient Outcome. Liver Transplantation, 24(11), pp.1512–1522. Available at: http://dx.doi.org/10.1002/lt.25197.
  2. Kollmann, D. et al., 2018. Expanding the donor pool: Donation after circulatory death and living liver donation do not compromise the results of liver transplantation. Liver Transplantation, 24(6), pp.779–789. Available at: http://dx.doi.org/10.1002/lt.25068.
  3. Kollmann, D. & Selzner, M., 2017. Recent advances in the field of warm ex-vivo liver perfusion. Current Opinion in Organ Transplantation, 22(6), pp.555–562. Available at: http://dx.doi.org/10.1097/MOT.0000000000000471.
  4. Kollmann, D. et al., 2018. PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma. OncoImmunology, 7(6), p.e1435226. Available at: http://dx.doi.org/10.1080/2162402X.2018.1435226.
  5. Kollmann, D. et al., 2017. Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma. Annals of Surgical Oncology, 24(9), pp.2698–2706. Available at: http://dx.doi.org/10.1245/s10434-017-5858-7.